Tafinlar 75mg (Dabrafenib Capsule) 75mg

Tafinlar 75mg capsules contain dabrafenib, a kinase inhibitor used in targeted cancer therapy. This oral treatment is prescribed for specific types of tumors. Store at room temperature and follow healthcare provider instructions closely.

Strength

75mg

Pack Size

120s

Storage

Ambient

Manufacturer / TM Owner

Novartis Pharma

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Tafinlar 75mg (dabrafenib) is used to treat certain cancers, including melanoma, non-small cell lung cancer, and thyroid cancer. It works by blocking proteins that promote cancer cell growth. This medication is often prescribed when cancer has spread or cannot be surgically removed. Always consult a doctor for personalized treatment plans.

Side Effects

Tafinlar 75mg may cause side effects such as fatigue, headache, or joint pain. Some users report fever or chills during treatment. Skin reactions like rash or dryness are also possible. These effects vary by individual and should be monitored by a healthcare professional.

Precautions & Warnings

Keep Tafinlar 75mg capsules at room temperature, away from moisture and heat. Avoid opening or crushing capsules to prevent exposure. Inform your doctor about all medications and health conditions before starting treatment. Regular check-ups are important to track progress and manage side effects.

Avoid Interactions

Tafinlar 75mg may interact with other medications, including strong CYP3A4 inhibitors or inducers. Avoid grapefruit products, as they can affect how the drug works. Discuss all prescriptions, over-the-counter drugs, and supplements with your healthcare provider to prevent harmful interactions.

Frequently Asked Questions

Tafinlar 75mg (dabrafenib) is used to treat certain cancers, including melanoma, non-small cell lung cancer, and thyroid cancer.

Store Tafinlar 75mg capsules at room temperature, away from moisture and heat. Keep them in the original container.

No, avoid opening or crushing Tafinlar 75mg capsules to prevent exposure to the medication.

Common side effects include fatigue, headache, joint pain, fever, and skin reactions like rash or dryness.

Yes, Tafinlar 75mg may interact with CYP3A4 inhibitors, inducers, and grapefruit products. Always consult your doctor before combining medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.